Maintenance treatment with ODM-201 in patients with castration-resistant metastatic prostate cancer (mCRPC) previously treated with new hormonal agents and non-progressive disease after receiving subsequent treatment with a taxane: Phase II, multicenter, randomized, double-blind study and placebo controlled
INDEPENDENT CLINICAL TRIAL
Clinical trial information
- Promoter: SPANISH GENITOURINARY ONCOLOGY GROUP (SOGUG)
- Phase: II
- Execution start: 30/01/2019
- End of execution: 30/12/2021
- IP: